Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Malignant Neoplasm
Interventions: Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more

Conditions: Metastatic Colorectal Cancer
Interventions: MEN1611, Cetuximab; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Phoenix, Arizona • Anaheim, California • Tacoma, Washington

Conditions: Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions: Topotecan, Gefitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Interventions: AZD3759, AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions: Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys; Other · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: RGT-419B, RGT-419B in combination with hormonal therapy; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more

Conditions: Relapsed Breast Cancer, Neoplasms, Breast
Interventions: Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Conditions: Advanced Solid Tumor, Metastatic Breast Cancer
Interventions: BTX-A51; Drug
Lead sponsor: Edgewood Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more

Conditions: NSCLC, Non Small Cell Lung Cancer
Interventions: OSI-906, Erlotinib, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: La Jolla, California • Tampa, Florida • Weston, Florida + 8 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 15
States / cities: Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Denver, Colorado • Bethesda, Maryland • Kettering, Ohio + 2 more

Conditions: Advanced Solid Tumors
Interventions: TAS-116; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Cleveland, Ohio • Greenville, South Carolina • Fairfax, Virginia

Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions: AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 23
States / cities: Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more

Conditions: EGFR Positive Solid Tumors
Interventions: IMGN289; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: Patritumab, Erlotinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 20 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Glendale, Arizona • Duarte, California • La Verne, California + 23 more

Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy; Biological · Drug
Lead sponsor: Genprex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions: Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa; Radiation · Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neoplasms, Breast
Interventions: lapatinib, docetaxel, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

A Study of PF-06873600 in People With Cancer

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

A Study of TAS-116 in Patients With Solid Tumors

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer